These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 9098653)

  • 21. [Travel vaccinations].
    Rothe C; Boecken G;
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 Jan; 63(1):74-84. PubMed ID: 31802155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationale for Japanese encephalitis vaccination in short-term travellers to endemic areas.
    Charoensakulchai S; Singhasenee P; Matsee W; Caumes E; Pisutsan P
    J Travel Med; 2024 Mar; 31(2):. PubMed ID: 38195999
    [No Abstract]   [Full Text] [Related]  

  • 23. IXIARO updated: overview of clinical trials and developments with the inactivated vaccine against Japanese encephalitis.
    Jelinek T
    Expert Rev Vaccines; 2013 Aug; 12(8):859-69. PubMed ID: 23984958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Japanese encephalitis: update on vaccines and vaccine recommendations.
    Wilder-Smith A; Halstead SB
    Curr Opin Infect Dis; 2010 Oct; 23(5):426-31. PubMed ID: 20581670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Unauthorized vaccines put on the market are useful for certain travelers].
    Chippaux A
    Bull Soc Pathol Exot; 1997; 90(4):240-2. PubMed ID: 9479460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Recent data on the epidemiology of Japanese encephalitis].
    Rodhain F
    Bull Acad Natl Med; 1996; 180(6):1325-37; discussion 1338-40. PubMed ID: 8991613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Japanese encephalitis].
    Jackson Y; Chappuis F; Loutan L
    Rev Med Suisse; 2007 May; 3(111):1233-6. PubMed ID: 17585626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.
    Yun KW; Lee HJ; Park JY; Cho HK; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
    Vaccine; 2018 Mar; 36(11):1398-1404. PubMed ID: 29429815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Japanese encephalitis vaccine and adverse effects among travellers.
    Robinson HC; Russell ML; Csokonay WM
    Can Dis Wkly Rep; 1991 Aug; 17(32):173-4, 177. PubMed ID: 1657420
    [No Abstract]   [Full Text] [Related]  

  • 30. Allergic mucocutaneous reactions to Japanese encephalitis vaccine.
    Plesner AM; Rønne T
    Vaccine; 1997 Aug; 15(11):1239-43. PubMed ID: 9286050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Vaccinations for overseas travelers--new evidence and recommendations].
    Stürchler MP; Steffen R
    Ther Umsch; 2001 Jun; 58(6):362-6. PubMed ID: 11441696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study.
    Kaltenböck A; Dubischar-Kastner K; Eder G; Jilg W; Klade C; Kollaritsch H; Paulke-Korinek M; von Sonnenburg F; Spruth M; Tauber E; Wiedermann U; Schuller E
    Vaccine; 2009 Jul; 27(33):4483-9. PubMed ID: 19486955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protection against Japanese encephalitis by inactivated vaccines.
    Hoke CH; Nisalak A; Sangawhipa N; Jatanasen S; Laorakapongse T; Innis BL; Kotchasenee S; Gingrich JB; Latendresse J; Fukai K
    N Engl J Med; 1988 Sep; 319(10):608-14. PubMed ID: 2842677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Vaccinations of the traveller].
    Marchou B; Picot N; Massip P
    Ann Med Interne (Paris); 1998 Oct; 149(6):332-9. PubMed ID: 9853043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis.
    Paulke-Korinek M; Kollaritsch H; Kundi M; Zwazl I; Seidl-Friedrich C; Jelinek T
    Vaccine; 2015 Jul; 33(30):3600-4. PubMed ID: 26036947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Superior immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (inactivated).
    Kikukawa A; Gomi Y; Akechi M; Onishi T; Manabe S; Namazue J; Fuke I; Ishikawa T; Okuno Y; Ueda S
    Vaccine; 2012 Mar; 30(13):2329-35. PubMed ID: 22306856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IC51 Japanese encephalitis vaccine.
    Kollaritsch H; Paulke-Korinek M; Dubischar-Kastner K
    Expert Opin Biol Ther; 2009 Jul; 9(7):921-31. PubMed ID: 19527110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Japanese encephalitis: new options for active immunization.
    Halstead SB; Thomas SJ
    Clin Infect Dis; 2010 Apr; 50(8):1155-64. PubMed ID: 20218889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Japanese encephalitis vaccination, with reference to travellers to Seoul, Korea.
    Can Dis Wkly Rep; 1988 Sep; 14(36):161-2. PubMed ID: 2852545
    [No Abstract]   [Full Text] [Related]  

  • 40. New Japanese encephalitis vaccines: alternatives to production in mouse brain.
    Halstead SB; Thomas SJ
    Expert Rev Vaccines; 2011 Mar; 10(3):355-64. PubMed ID: 21434803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.